US 12,215,347 B2
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
Michael Thomas Bethune, Castro Valley, CA (US); Yi Zhang, Foster City, CA (US); Thomas John Van Blarcom, Oakland, CA (US); Siler Panowski, Barkeley, CA (US); and Barbra Johnson Sasu, San Francisco, CA (US)
Assigned to Allogene Therapeutics, Inc., South San Francisco, CA (US)
Filed by Allogene Therapeutics, Inc., South San Francisco, CA (US)
Filed on Jul. 21, 2021, as Appl. No. 17/381,693.
Claims priority of provisional application 63/219,710, filed on Jul. 8, 2021.
Claims priority of provisional application 63/054,701, filed on Jul. 21, 2020.
Prior Publication US 2022/0023346 A1, Jan. 27, 2022
Int. Cl. C12N 5/0783 (2010.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C12N 15/86 (2006.01)
CPC C12N 5/0636 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464402 (2023.05); C07K 14/7051 (2013.01); C12N 15/86 (2013.01); A61K 2239/22 (2023.05)] 12 Claims
OG exemplary drawing
 
1. A recombinant antigen receptor comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular domain that comprises a co-stimulatory domain and an ITAM-containing domain, wherein
the ITAM-containing domain comprises from N-terminus to C-terminus (a) CD3z1 ITAM, CD3d ITAM, CD3z2 ITAM, CD3e ITAM, CD3z3 ITAM, CD3g ITAM, (b) CD3z1 (YAEL (SEQ ID NO: 152)) ITAM, CD3z2 (YAEL (SEQ ID NO: 152)) ITAM, CD3z3 (YAGL (SEQ ID NO: 153)) ITAM, or (c) CD3z1 (YAEL (SEQ ID NO: 152)) ITAM, CD3d (YAPL (SEQ ID NO: 154)) ITAM, CD3z2 (YAEL (SEQ ID NO: 152)) ITAM, CD3e (YAPI (SEQ ID NO: 155)) ITAM, CD3z3 (YAGL (SEQ ID NO: 153)) ITAM, CD3g (YAPL (SEQ ID NO: 154)) ITAM.